Previous 10 | Next 10 |
2023-05-05 18:33:14 ET Nanoviricides ( NYSE: NNVC ) has filed for a $150M mixed shelf securities offering. The company indicated it plans to use the proceeds for general corporate purposes. The offering can include common stock, preferred stock, debt securities, warran...
NanoViricides (NYSE American: NNVC) , a clinical-stage global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, will be participating at the inaugural EF Hutton Global Conference. The two-day event is scheduled for May 10–1...
SHELTON, Conn., May 04, 2023 (GLOBE NEWSWIRE) -- (via IBN) -- NanoViricides, Inc. (NYSE American: NNVC ) (the “Company”), a clinical stage global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, announces that...
NanoViricides (NYSE American: NNVC) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide(R) class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Our lead drug ca...
2023-04-25 09:15:55 ET NanoViricides ( NYSE: NNVC ) said it is exploring other antiviral applications for the active pharmaceutical ingredient in NV-387, its COVID-19 candidate. The company said that NV-387 has demonstrated broad spectrum activity against seasonal cor...
SHELTON, CT / ACCESSWIRE / April 25, 2023 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical stage global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, reports that it is exploring additional antiviral application...
SHELTON, CT / ACCESSWIRE / April 17, 2023 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical stage global leader in nanomedicines against viruses, announced today that it has shipped the drug products for impending clinical trials of NV-CoV-2, its COVID drug candidate, to i...
--News Direct-- NanoViricides CEO Anil Diwan joined Steve Darling from Proactive to share news about the company that is using its nanoviricide platform technology to develop drugs that fight against viruses. Diwan tells Proactive some of the drugs in development include its most advanced...
2023-04-06 13:25:31 ET Gainers: Guardforce AI ( GFAI ) +61% . Amesite ( AMST ) +31% . Tellurian ( TELL ) +29% . The Singing Machine Company ( MICS ) +27% . Cardlytics ( CDLX ) +22% . Finance Of America Companies ( FOA ) ...
SHELTON, CT / ACCESSWIRE / April 4, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in nanomedicines against viruses, announced today that it has executed a License Agreement with Karveer Meditech Pvt. Ltd., Kolhapur, India ("Karveer"). Under this Agreement, K...
News, Short Squeeze, Breakout and More Instantly...
SHELTON, CT / ACCESSWIRE / July 11, 2024 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, discusses its development program for NV-387, a single drug that has shown activity against many respiratory viral infe...
SHELTON, CT / ACCESSWIRE / July 1, 2024 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical-stage global leader in broad-spectrum antiviral nanomedicines, elaborates on its current assets and plans towards becoming a successful pharmaceutical company intending to revolutioni...
--News Direct-- NanoViricides CEO Dr Anil Diwan joined Steve Darling from Proactive to share promising news about the company's ultra-broad-spectrum antiviral, NV-387. The antiviral was found to be effective in protecting lungs from damage in a lethally infected Influenza A H3N2 mouse mod...